Payment overview · 2025
General Payments
$2,640.76
97 reported records · 19 companies
Healthcare provider profile · identity verified
Caleb Firmstone Dunlap, MD
Allopathic & Osteopathic Physicians|Family Medicine · JACKSONVILLE, FL · NPI 1104386473
Verified facts
What the public records show
CMS Open Payments records show Caleb Firmstone Dunlap, MD received $2,640.76 in general payments during 2025 across 97 reported records.
AstraZeneca Pharmaceuticals LP accounted for 20.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Farxiga, Jardiance, Kerendia, Mounjaro, Trelegy Ellipta, Vraylar.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported VRAYLAR as an associated drug or biological on 377741 records involving 62704 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Vraylar by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 60 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 23 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 108 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 97 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Trulicity by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ABRYSVO as an associated drug or biological on 55380 records involving 31565 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Abrysvo by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 314 claims for Eliquis by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $547.24 | 20.7% | 12 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $324.08 | 12.3% | 10 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $291.45 | 11.0% | 13 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $267.82 | 10.1% | 13 | 2025 |
| Otsuka America Pharmaceutical, Inc. | Unresolved — no canonical attribution shown | $207.62 | 7.9% | 9 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $200.67 | 7.6% | 8 | 2025 |
| Ethicon Inc. | Unresolved — no canonical attribution shown | $188.86 | 7.2% | 1 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $119.16 | 4.5% | 7 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $67.49 | 2.6% | 4 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $64.18 | 2.4% | 3 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $63.84 | 2.4% | 4 | 2025 |
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$50.23 | 1.9% | 1 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $47.37 | 1.8% | 2 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $45.87 | 1.7% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $44.39 | 1.7% | 3 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $36.58 | 1.4% | 2 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $33.91 | 1.3% | 1 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $21.10 | 0.8% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $18.90 | 0.7% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $2,640.76 | 97 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $349.23 | 5 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $333.62 | 5 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $324.08 | 10 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $267.82 | 13 | 2025 |
Source payment records
|
|||||
| REXULTI Normalized: rexulti |
Drug | Otsuka America Pharmaceutical, Inc. | $207.62 | 9 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $196.05 | 2 | 2025 |
Source payment records
|
|||||
| Monarch Platform Normalized: monarch platform |
Device | Ethicon Inc. | $188.86 | 1 | 2025 |
Source payment records
|
|||||
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $176.57 | 7 | 2025 |
Source payment records
|
|||||
| VRAYLAR Normalized: vraylar |
Drug | ABBVIE INC. | $163.28 | 7 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $128.17 | 6 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $84.53 | 5 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $67.49 | 4 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $64.18 | 3 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $63.84 | 4 | 2025 |
Source payment records
|
|||||
| MINIMED 780G Normalized: minimed 780g |
Device | Medtronic, Inc. | $50.23 | 1 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $47.37 | 2 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $46.37 | 3 | 2025 |
Source payment records
|
|||||
| Extended Holter Normalized: extended holter |
Device | Philips North America LLC | $45.87 | 2 | 2025 |
Source payment records
|
|||||
| PROLIA Normalized: prolia |
Biological | Amgen Inc. | $42.22 | 3 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $36.58 | 2 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $36.58 | 2 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $33.91 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $30.49 | 2 | 2025 |
Source payment records
|
|||||
| TEPEZZA Normalized: tepezza |
Biological | Amgen Inc. | $24.10 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Lilly USA, LLC | $21.99 | 1 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $21.10 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $18.90 | 1 | 2025 |
Source payment records
|
|||||
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $16.34 | 1 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $13.90 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 32 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 36 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 97 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 108 | exact normalized | Medicare Part D |
| VRAYLAR vraylar |
2025 | Vraylar | 2024 | 68 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
37 | 12 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | VRAYLAR open payments reported associated product |
CMS Open Payments — General Payments 377741 supporting records · 62704 recipient NPIs · example record 1201352550 |
Vraylar · 2024 Exact normalized brand match · 1 Part D row |
68 | 13 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
60 | 19 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
23 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
32 | 13 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
108 | 28 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
36 | 14 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
97 | 17 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ABRYSVO open payments reported associated product |
CMS Open Payments — General Payments 55380 supporting records · 31565 recipient NPIs · example record 1228794147 |
Abrysvo · 2024 Exact normalized brand match · 1 Part D row |
14 | 14 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
314 | 60 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 612 | 163 |
| Gabapentin | Gabapentin | 357 | 106 |
| Omeprazole | Omeprazole | 353 | 93 |
| Levothyroxine Sodium | Levothyroxine Sodium | 331 | 95 |
| Amlodipine Besylate | Amlodipine Besylate | 319 | 126 |
| Eliquis | Apixaban | 314 | 60 |
| Sertraline Hcl | Sertraline Hcl | 305 | 39 |
| Pantoprazole Sodium | Pantoprazole Sodium | 242 | 85 |
| Lisinopril | Lisinopril | 226 | 67 |
| Tamsulosin Hcl | Tamsulosin Hcl | 217 | 62 |
| Metformin Hcl | Metformin Hcl | 216 | 52 |
| Buspirone Hcl | Buspirone Hcl | 186 | 45 |
| Losartan Potassium | Losartan Potassium | 180 | 63 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 178 | 59 |
| Carvedilol | Carvedilol | 176 | 62 |
| Metoprolol Tartrate | Metoprolol Tartrate | 171 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 170 | 68 |
| Trazodone Hcl | Trazodone Hcl | 167 | 55 |
| Montelukast Sodium | Montelukast Sodium | 161 | 43 |
| Metoprolol Succinate | Metoprolol Succinate | 148 | 55 |
| Tizanidine Hcl | Tizanidine Hcl | 138 | 59 |
| Clopidogrel | Clopidogrel Bisulfate | 137 | 39 |
| Furosemide | Furosemide | 132 | 48 |
| Potassium Chloride | Potassium Chloride | 129 | 28 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 108 | 28 |
| Famotidine | Famotidine | 102 | 26 |
| Ozempic | Semaglutide | 101 | 29 |
| Nifedipine Er | Nifedipine | 100 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 97 | 32 |
| Mounjaro | Tirzepatide | 97 | 17 |
| Entresto | Sacubitril/Valsartan | 93 | 11 |
| Quetiapine Fumarate | Quetiapine Fumarate | 89 | 28 |
| Meloxicam | Meloxicam | 88 | 48 |
| Levetiracetam | Levetiracetam | 83 | 14 |
| Memantine Hcl | Memantine Hcl | 81 | 12 |
| Amiodarone Hcl | Amiodarone Hcl | 80 | 11 |
| Fluticasone Propionate | Fluticasone Propionate | 79 | 37 |
| Escitalopram Oxalate | Escitalopram Oxalate | 77 | 30 |
| Pravastatin Sodium | Pravastatin Sodium | 76 | 25 |
| Spironolactone | Spironolactone | 74 | 23 |
| Aripiprazole | Aripiprazole | 73 | suppressed |
| Simvastatin | Simvastatin | 73 | 26 |
| Azithromycin | Azithromycin | 69 | 59 |
| Valsartan | Valsartan | 69 | 12 |
| Vraylar | Cariprazine Hcl | 68 | 13 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 65 | 38 |
| Hydralazine Hcl | Hydralazine Hcl | 64 | 18 |
| Celecoxib | Celecoxib | 63 | 23 |
| Myrbetriq | Mirabegron | 60 | 19 |
| Ziprasidone Hcl | Ziprasidone Hcl | 60 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 57 | 24 |
| Donepezil Hcl | Donepezil Hcl | 56 | 13 |
| Alprazolam | Alprazolam | 54 | 16 |
| Midodrine Hcl | Midodrine Hcl | 54 | suppressed |
| Naproxen | Naproxen | 53 | 21 |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 53 | 19 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 52 | 12 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 52 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 51 | 25 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 51 | 18 |
| Methenamine Hippurate | Methenamine Hippurate | 51 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 49 | suppressed |
| Insulin Aspart Flexpen | Insulin Aspart | 48 | 15 |
| Mirtazapine | Mirtazapine | 48 | 24 |
| Cephalexin | Cephalexin | 47 | 31 |
| Ropinirole Hcl | Ropinirole Hcl | 46 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 45 | 22 |
| Zolpidem Tartrate | Zolpidem Tartrate | 44 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 43 | 11 |
| Allopurinol | Allopurinol | 42 | 17 |
| Ondansetron Odt | Ondansetron | 41 | 18 |
| Tresiba Flextouch U-200 | Insulin Degludec | 41 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 40 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 40 | suppressed |
| Januvia | Sitagliptin Phosphate | 40 | suppressed |
| Levemir Flexpen | Insulin Detemir | 39 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 38 | 36 |
| Doxazosin Mesylate | Doxazosin Mesylate | 38 | suppressed |
| Methocarbamol | Methocarbamol | 38 | 25 |
| Testosterone Cypionate | Testosterone Cypionate | 38 | 15 |
| Glipizide Er | Glipizide | 37 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 37 | suppressed |
| Linzess | Linaclotide | 37 | 12 |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 36 | 11 |
| Clonazepam | Clonazepam | 36 | suppressed |
| Ezetimibe | Ezetimibe | 36 | 17 |
| Ibandronate Sodium | Ibandronate Sodium | 36 | 15 |
| Jardiance | Empagliflozin | 36 | 14 |
| Clobetasol Propionate | Clobetasol Propionate | 35 | 12 |
| Meclizine Hcl | Meclizine Hcl | 35 | 21 |
| Bumetanide | Bumetanide | 34 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | suppressed |
| Ibuprofen | Ibuprofen | 34 | 21 |
| Metformin Hcl Er | Metformin Hcl | 34 | suppressed |
| Mexiletine Hcl | Mexiletine Hcl | 34 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 33 | 27 |
| Farxiga | Dapagliflozin Propanediol | 32 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 32 | 12 |
| Tramadol Hcl | Tramadol Hcl | 32 | 19 |
| Ventolin Hfa | Albuterol Sulfate | 32 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 31 | 12 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 31 | 13 |
| Prednisone | Prednisone | 31 | 22 |
| Bupropion Xl | Bupropion Hcl | 30 | 14 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 23 |
| Doxycycline Hyclate | Doxycycline Hyclate | 30 | 22 |
| Promethazine Hcl | Promethazine Hcl | 30 | suppressed |
| Diltiazem Hcl | Diltiazem Hcl | 29 | suppressed |
| Ketoconazole | Ketoconazole | 29 | 11 |
| Sucralfate | Sucralfate | 29 | 14 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 29 | 13 |
| Atenolol | Atenolol | 28 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 28 | 14 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Methylprednisolone | Methylprednisolone | 28 | 23 |
| Nystatin | Nystatin | 28 | 17 |
| Novolog Flexpen | Insulin Aspart | 27 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 26 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 26 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 25 | 15 |
| Finasteride | Finasteride | 25 | 14 |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 24 | suppressed |
| Brilinta | Ticagrelor | 23 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 22 | suppressed |
| Multaq | Dronedarone Hcl | 22 | suppressed |
| Baclofen | Baclofen | 21 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 21 | suppressed |
| Elmiron | Pentosan Polysulfate Sodium | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 16 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 21 | 11 |
| Primidone | Primidone | 21 | suppressed |
| Eszopiclone | Eszopiclone | 20 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 20 | 16 |
| Topiramate | Topiramate | 20 | suppressed |
| Trulicity | Dulaglutide | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 19 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 19 | suppressed |
| Lidocaine | Lidocaine | 19 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 19 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 18 | suppressed |
| Restasis | Cyclosporine | 18 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 17 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 17 | suppressed |
| Glimepiride | Glimepiride | 17 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 17 | suppressed |
| Levofloxacin | Levofloxacin | 17 | suppressed |
| Mupirocin | Mupirocin | 17 | 12 |
| Pioglitazone Hcl | Pioglitazone Hcl | 17 | suppressed |
| Risperidone | Risperidone | 17 | suppressed |
| Scopolamine | Scopolamine | 17 | suppressed |
| Sildenafil Citrate | Sildenafil Citrate | 17 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 17 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 17 | suppressed |
| Cefdinir | Cefdinir | 16 | 13 |
| Colchicine | Colchicine | 16 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 16 | suppressed |
| Lorazepam | Lorazepam | 16 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 16 | suppressed |
| Xarelto | Rivaroxaban | 16 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 15 | 13 |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 14 | 14 |
| Estradiol | Estradiol | 14 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 14 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 14 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 14 | suppressed |
| Temazepam | Temazepam | 14 | suppressed |
| Chlorthalidone | Chlorthalidone | 13 | suppressed |
| Hydroxyurea | Hydroxyurea | 13 | suppressed |
| Vyvanse | Lisdexamfetamine Dimesylate | 13 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 12 | suppressed |
| Lurasidone Hcl | Lurasidone Hcl | 12 | suppressed |
| Megestrol Acetate | Megestrol Acetate | 12 | suppressed |
| Metolazone | Metolazone | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 12 | suppressed |
| Prazosin Hcl | Prazosin Hcl | 12 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 12 | 11 |
| Doxepin Hcl | Doxepin Hcl | 11 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Letrozole | Letrozole | 11 | suppressed |
| Repaglinide | Repaglinide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $2,640.76 · 97 records | AstraZeneca Pharmaceuticals LP | AIRSUPRA, BREZTRI, CAPLYTA, Cologuard Collection Kit, DUPIXENT, Dexcom G6 Transmitter, EVENITY, Extended Holter, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, JARDIANCE, Kerendia, MINIMED 780G, MOUNJARO, Monarch Platform, NURTEC ODT, PROLIA, QULIPTA, REXULTI, TEPEZZA, TRELEGY ELLIPTA, TZIELD, The Cologuard Plus Collection Kit, UBRELVY, VRAYLAR, Veozah, ZAVZPRET, ZEPBOUND | 13 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Farxiga play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error